Previous research studies

Since 1988 the department has been involved in clinical research. The unit has a reputation for providing high quality data and participation in a wide variety of collaborative studies with local, national and international commercial and academic partners. These include Brighton and Sussex Medical School, the World Health Organisation, the National Institute for Health Research.

 

Main areas of research

New therapies to treat and prevent HIV including Pre & Post Exposure Prophylaxis (PEP & PrEP)

Strategy studies – how best to use the drugs available and when to start

Effects of HIV combined with ageing and other medical conditions.

Impact on future service delivery

Novel testing and treatment approaches for Sexually Transmitted Infections

 

 

Examples of some of the previous research studies carried out with our team:

 

 

 

0111 – Study to Evaluate the Safety and Efficacy of E/C/F/TAF (Genvoya®) Versus E/C/F/TDF (Stribild®) in HIV-1 Positive, Antiretroviral Treatment-Naive Adults
0112 – Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
0109 – Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants
1089 – Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF
1844 (Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF )
1489 (Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine )
1878 (Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide )
0109 (Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination)
0122 (Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection)
2055 (DISCOVER PrEP study)

 

 

 

 

GEMINI 2

 

 

 

 

DRIVE SHIFT
DRIVE FORWARD
DRIVE AHEAD
EMERALD

 

 

 

 

RIVER
START – Strategic Timing of AntiRetroviral Treatment

 

 

 

 

047 – A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine
056 – Efavirenz to Dolutegravir Switch in Patients With CNS Toxicity
058 – Atripla to Eviplera Switch in Patients Without Central Nervous System Symptoms
060 (NEAT) – Cardiovascular Risk in HIV Patients Switching From a Boosted Protease Inhibitor (PI) to Dolutegravir (DTG).
Also see article printed in NAM
064 – Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over
058
064
056
ONCE
IMPACT – NHS England PrEP study

 

 

 

 

 

PRIME
POSITIVE VOICES

 

POPPY
POPPY SLEEP  (Sub study of POPPY)

 


Want to be part of our research?

{{message}}